Promising Clinical Trial in Breast Cancer

breast-cancer
Doctor of master Michelangelo Quintela has published in the prestigious British Journal of Cancer a promising clinical trial in which a complete remission of patients with early breast cancer is observed type HER-2-negative, the most common type with nintedanib drug combination in combination with standard chemotherapy with paclitaxel.

The combination of paclitaxel and nintedanib drugs has proved successful, since it has proved totally secure and yielded a pathological complete response rate of 50%, twice the one obtained with standard therapy with paclitaxel. The trial included a dozen HER2-negative breast cancer patients, all in early stages of the disease.

In view of the results, the Clinical Research Unit of the CNIO Breast Cancer has launched a large-scale clinical study in phase II to validate the study in a larger number of patients. The results, including the study of biomarkers that enable the customization therapeutic, is expected in early 2015.

Parallel, Unit has just completed a second clinical phase I trial with a drug like this, el dovitinib, in metastatic patients of different origin as breast, colon lung. Study, still preliminary, suggests that patients with a specific variant of the gene RET proto-oncogene-a gene promoter or tumor; G2071A- variant may be more sensitive to the drug. The work is published in the journal Molecular Oncology.

If these data are confirmed, this genetic variant, present in 15% Caucasian population, could be used as targeting biomarker for selecting personalized medicine robustly and low cost-as only 6 Euros candidates aquellos patients receiving drug it.

Nintedanib, is an anti-angiogenic receptor blocking vascular endothelial growth factor (VEGFR) growth factor and platelet-derived (PDGFR), also acts unlike classical angiogenic, receptors for fibroblast growth factor (FGFR). These work by aberrantly 10-15% cancers of HER2-negative, which may explain the increased antitumor activity of the compound compared with its analogues. The compound has shown excellent results in phase III trials in lung cancer and ovarian.